SCHEMBL19169674

SCHEMBL19169674

Cc1nc(-n2c3ccccc3c3ccccc32)c2c(n1)oc1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.44
▸ LMNA P02545 4/20 0.44
▸ ALDH1A1 P00352 6/20 0.42
▸ HSD17B10 Q99714 5/20 0.42
▸ HPGD P15428 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ MAPK1 P28482 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ DUSP3 P51452 1/20 0.42
▸ PTPN5 P54829 1/20 0.42
▸ PTPN11 Q06124 1/20 0.42
▸ HRH4 Q9H3N8 1/20 0.40
▸ CREBBP Q92793 1/20 0.40
▸ PSMD14 O00487 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16905826 0.84 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL19161278 0.83 SMN1; SMN2 (0.40) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL16905829 0.81 TSHR (0.42) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL16905831 0.78 SMN1; SMN2 (0.41) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL19169535 0.77 SMN1; SMN2 (0.44) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL25847178 0.77 SMN1; SMN2 (0.44) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL16905824 0.77 EGFR (0.38) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL24816077 0.75 HPGD (0.44) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL19679700 0.75 AHR (0.37) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD
SCHEMBL19170196 0.75 SMN1; SMN2 (0.46) SMN1; SMN2LMNAALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170213984-A1 NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME LG CHEM, LTD. (KR) 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170213984-A1 NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME CRY1, NOS1, NOLC1 SMN1; SMN2 3568/4885LMNA 3140/4885ALDH1A1 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback